Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs

Elborn, J. S.; Prescott, R. J.; Stack, B. H. R.; Goodchild, M. C.; Bates, J.; Pantin, C.; Ali, N.; Shale, D. J.; Crane, M.
May 2000
Thorax;May2000, p355
Academic Journal
No abstract available.


Related Articles

  • Knock Out CF Lung Infections. Harrar, Sari; Metcalf, Eric // Prevention;Mar2002, Vol. 54 Issue 3, p151 

    Reports that the antibiotic tobramycin can prevent the bacteria Pseudomonas aeruginosa from infecting the lungs of people with cystic fibrosis.

  • Prospects for the Prevention and Control of Pseudomonal Infection in Children with Cystic Fibrosis. Høiby, N. // Pediatric Drugs;Nov/Dec2000, Vol. 2 Issue 6, p451 

    Most patients with cystic fibrosis (CF) experience recurrent and chronic endobronchial Pseudomonas aeruginosa infections. It is possible to prevent or delay the onset of these chronic infections in most patients with CF by eliminating cross-infection and by early aggressive antibiotic treatment...

  • Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Høiby, Niels // BMC Medicine;2011, Vol. 9 Issue 1, p32 

    Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients is caused by biofilmgrowing mucoid strains. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated by chronic suppressive therapy. New results from one small trial...

  • Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa. Van Gennip, Maria; Moser, Claus; Christensen, Louise D.; Bjarnsholt, Thomas; Calum, Henrik; Jensen, Peter Ø.; Christophersen, Lars; Hougen, Hans Petter; Ciofu, Oana; Molin, Søren; Givskov, Michael; Høiby, Niels // Journal of Antimicrobial Chemotherapy (JAC);Dec2009, Vol. 64 Issue 6, p1241 

    Background: Effects of treatment with tobramycin initiated 1 or 24 h post-infection were investigated in a new version of a pulmonary infection model in mice. The model reflects the differentiated behaviour of Pseudomonas aeruginosa mucoid strains isolated from the lungs of one chronically...

  • Clinical trial to test success of cystic fibrosis lung infection treatment.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that the intravenous antibiotics are being tested for treating cystic fibrosis complications effectively in patients with lung infection.

  • Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis. Adis International Limited // Drugs & Therapy Perspectives;Sep2004, Vol. 20 Issue 9, p1 

    Focuses on the effects of inhaled tobramycin on lung function and bacterial density associated with Pseudomonas aeruginosa infections in cystic fibrosis patients. Clinical benefits and potential limitations of tobramycin solution for inhalation (TSI) in the management of Pseudomonas aeruginosa...

  • CITATIONS AND CLINICIANS' NOTES: CYSTIC FIBROSIS.  // Current Medical Literature: Respiratory Medicine;2004, Vol. 18 Issue 1, p26 

    Presents citations and clinicians' notes on studies on cystic fibrosis. "Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL," by N. Reinhardt, et al; "Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease,"...

  • Pseudomonas Vaccine. Stephenson, Joan // JAMA: Journal of the American Medical Association;7/18/2007, Vol. 298 Issue 3, p277 

    This article examines a study that found a vaccine targeting proteins of the flagella of Pseudomonas aeruginosa reduced the risk of initial infection in patients with cystic fibrosis. Life-threatening chronic lung infections caused by P aeruginosa are the leading cause of death in patients with...

  • Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis. Burns, Jane L.; Van Dalfsen, Jill M.; Shawar, Ribhi M.; Otto, Kelly L.; Garber, Richard L.; Quan, Joanne M.; Montgomery, A. Bruce; Albers, Gary M.; Ramsey, Bonnie W.; Smith, Arnold L. // Journal of Infectious Diseases;5/1/99, Vol. 179 Issue 5, p1190 

    Examines the effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Effects of pseudomonas aeruginosa endobronchial infection; Patient population; Use of oral and parenteral antibiotics; Isolation of intrinsically...

  • Minimizing the toxicity of aminoglycosides in cystic fibrosis. Smyth, Alan R. // Journal of the Royal Society of Medicine (Supplement);Jul2010, Vol. 103 Issue 3, pS3 

    The article reports on a large number of cystic fibrosis patients in Great Britain who develop chronic pulmonary infection with Pseudomonas aeruginosa by their late teenage years. A discussion of the benefits that the patients can obtain from using intravenous antibiotics to treat the...


Read the Article


Sign out of this library

Other Topics